Yazar "Bondarenko, I." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1(Elsevier Science Inc, 2021) Bondarenko, I.; Sezer, A.; Kilickap, S.; Gumus, M.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(Elsevier Science Inc, 2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update(Elsevier Science Inc, 2023) Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%(Elsevier, 2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial(Elsevier, 2022) Ho, G. F.; Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]Öğe Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Garassino, M. C.; Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]
